Alcon announced in early August that it has entered into a definitive merger agreement with Staar, under which Alcon will ...

Broadwood Partners, STAAR's largest shareholder, opposes the Alcon merger, citing board conflicts and rushed decision-making.

If you have been wondering what to do with Alcon stock lately, you are definitely not alone. With shares closing at $61.12 and recent moves showing a 2.0% gain over the past week and a 3.7% increase ...

The special meeting to vote on the company's $1.5 billion sale to Alcon, originally scheduled for today, has been adjourned ...

STAAR Surgical Company (NASDAQ:STAA) privately asked Alcon AG (NYSE:ALC) to sweeten its $28-per-share takeover offer, but Alcon rejected the request, according to supplemental proxy materials filed ...

Alcon has experienced robust Q1 growth, driven by double-digit growth in vision care, particularly in the contact lens market. The company's strong revenue growth is attributed to successful product ...

STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for moderate to high myopes Acquisition of STAAR is complementary to Alcon's laser vision ...

Millions of contact lens wearers navigating busy schedules and long hours on screens are seeking a balance of comfort and ...

Please provide your email address to receive an email when new articles are posted on . Alcon will buy Lensar’s outstanding shares for $14 per share. The deal is expected to close in the second half ...

Former Novartis subsidiary Alcon, after targeting the pharmaceutical eye drop scene with a trio of recent drug purchases, is adding another pair of arrows to its ophthalmic quiver. And this time, the ...

Alcon Laboratories, already one of the largest employers and taxpayers in Tarrant County, is exploring a major expansion of its Fort Worth campus. Alcon, which started in Fort Worth and has grown to ...

Eye care giant Alcon appears to have gained the upper hand in the ongoing power struggle with Aurion Biotech by securing a majority stake in the clinical-stage company and replacing its CEO. The move ...